[go: up one dir, main page]

MA37762A1 - Composés n-aryltriazole utilisés comme antagonistes de lpar - Google Patents

Composés n-aryltriazole utilisés comme antagonistes de lpar

Info

Publication number
MA37762A1
MA37762A1 MA37762A MA37762A MA37762A1 MA 37762 A1 MA37762 A1 MA 37762A1 MA 37762 A MA37762 A MA 37762A MA 37762 A MA37762 A MA 37762A MA 37762 A1 MA37762 A1 MA 37762A1
Authority
MA
Morocco
Prior art keywords
lpar
antagonists
compounds used
aryltriazole
compounds
Prior art date
Application number
MA37762A
Other languages
English (en)
Other versions
MA37762B1 (fr
Inventor
Stephen Deems Gabriel
Matthew Michael Hamilton
Yimin Qian
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48628669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37762(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA37762A1 publication Critical patent/MA37762A1/fr
Publication of MA37762B1 publication Critical patent/MA37762B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des composés de formule (i) ainsi que des sels pharmaceutiquement acceptables de ceux-ci, les substituants étant ceux qui sont indiqués dans la description. Ces composés, et les compositions pharmaceutiques les contenant, sont utiles pour le traitement de maladies et de troubles inflammatoires tels que le fibrose pulmonaire par exemple.
MA37762A 2012-06-20 2013-06-17 Composés n-aryltriazole utilisés comme antagonistes de lpar MA37762B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661953P 2012-06-20 2012-06-20
PCT/EP2013/062463 WO2013189865A1 (fr) 2012-06-20 2013-06-17 Composés n-aryltriazole utilisés comme antagonistes de lpar

Publications (2)

Publication Number Publication Date
MA37762A1 true MA37762A1 (fr) 2017-07-31
MA37762B1 MA37762B1 (fr) 2018-04-30

Family

ID=48628669

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37762A MA37762B1 (fr) 2012-06-20 2013-06-17 Composés n-aryltriazole utilisés comme antagonistes de lpar

Country Status (22)

Country Link
US (1) US20150133512A1 (fr)
EP (1) EP2864301A1 (fr)
JP (1) JP2015520203A (fr)
KR (1) KR20150011389A (fr)
CN (1) CN104395299A (fr)
AU (1) AU2013279513A1 (fr)
BR (1) BR112014030674A2 (fr)
CA (1) CA2869564A1 (fr)
CL (1) CL2014003241A1 (fr)
CO (1) CO7131357A2 (fr)
EA (1) EA201492281A1 (fr)
HK (1) HK1206339A1 (fr)
IL (1) IL236087A0 (fr)
IN (1) IN2014DN09352A (fr)
MA (1) MA37762B1 (fr)
MX (1) MX2014014711A (fr)
PE (1) PE20142305A1 (fr)
PH (1) PH12014502363A1 (fr)
SG (1) SG11201407228PA (fr)
UA (1) UA110310C2 (fr)
WO (1) WO2013189865A1 (fr)
ZA (1) ZA201408167B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104066729A (zh) 2011-08-15 2014-09-24 英特穆恩公司 溶血磷脂酸受体拮抗剂
TW201437200A (zh) * 2013-01-15 2014-10-01 Intermune Inc 溶血磷脂酸受體拮抗劑
SG11201507459YA (en) 2013-03-15 2015-10-29 Epigen Biosciences Inc Heterocyclic compounds useful in the treatment of disease
UY36060A (es) 2014-04-02 2015-10-30 Bayer Pharma AG Compuestos de azol sustituidos con amida
US10023554B2 (en) 2014-06-27 2018-07-17 Ube Industries, Ltd. Halogen-substituted heterocyclic compound salt
WO2017055313A1 (fr) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Composés azole amido-substitués
WO2017055316A1 (fr) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Composés azole à substitution amido
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
WO2018078009A1 (fr) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Dérivés de cyclohexane à substitution amido
WO2018078005A1 (fr) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Dérivés d'azaspiro à substitution amido en tant qu'inhibiteurs de tankyrase
WO2018087126A1 (fr) 2016-11-09 2018-05-17 Bayer Pharma Aktiengesellschaft Dérivés de cyclohexane à substitution amido en tant qu'inhibiteurs de tankyrase
CN107827829A (zh) * 2017-11-07 2018-03-23 大连理工大学 5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑在水相及生物介质中的制备方法
CN107721984A (zh) * 2017-11-07 2018-02-23 大连理工大学 一种新型5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑的制备方法
ES2924704T3 (es) 2017-12-19 2022-10-10 Bristol Myers Squibb Co Pirazol azoles del ácido ciclohexílico como antagonistas de LPA
WO2019126099A1 (fr) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Acides carbamoyle cyclohexyliques à liaison n isoxazole utilisés en tant qu'antagonistes de lpa
WO2019126087A1 (fr) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Acide cyclohexyle isoxazole azoles en tant qu'antagonistes de lpa
CA3085938A1 (fr) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Azoles triazoles d'acide cyclohexyle utilises en tant qu'antagonistes de lpa
EA202091500A1 (ru) 2017-12-19 2020-09-14 Бристол-Маерс Сквибб Компани Пиразол n-связанные карбамоилциклогексильные кислоты в качестве антагонистов lpa
JP7526096B2 (ja) * 2017-12-19 2024-07-31 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアジン
US11261174B2 (en) 2017-12-19 2022-03-01 Bristol-Myers Squibb Company Pyrazole O-linked carbamoyl cyclohexyl acids as LPA antagonists
WO2019126089A1 (fr) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Azines pyrazoles d'acide cyclohexyle utilisés en tant qu'antagonistes de lpa
ES2936517T3 (es) 2017-12-19 2023-03-17 Bristol Myers Squibb Co Triazol azinas de ácido ciclohexílico como antagonistas de LPA
EP3728240B1 (fr) * 2017-12-19 2022-06-29 Bristol-Myers Squibb Company Acides carbamoyle cyclohexyliques à liaison o isoxazole utilisés en tant qu'antagonistes de lpa
EP3853232B1 (fr) 2018-09-18 2023-03-01 Bristol-Myers Squibb Company Oxabicyclo-acides en tant qu'antagonistes de lpa
US12209072B2 (en) 2018-09-18 2025-01-28 Bristol-Myers Squibb Company Cyclopentyl acids as LPA antagonists
CN111434653A (zh) 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 三氮唑类化合物及其制备方法与用途
CN114728168B (zh) 2019-11-15 2024-04-09 吉利德科学公司 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
AU2021282986B2 (en) 2020-06-03 2024-03-07 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
KR20240005892A (ko) 2021-05-11 2024-01-12 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
AU2022405082B2 (en) 2021-12-08 2025-09-25 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
CN115745848A (zh) * 2022-12-07 2023-03-07 上海优合生物科技有限公司 一种氨基胍的加工合成工艺

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159550A2 (fr) * 2010-06-14 2011-12-22 Amidra Pharmaceuticals, Inc. Antagoniste du récepteur de l'acide lysophosphatidique et ses utilisations
WO2011159633A1 (fr) * 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Formulations inhalables d'antagonistes de récepteur d'acide lysophosphatidique
BR112013014019A2 (pt) * 2010-12-07 2016-09-13 Amira Pharmaceuticals Inc antagonistas do receptor do ácido lisofosfatídico e seus usos
WO2012138648A1 (fr) * 2011-04-06 2012-10-11 Irm Llc Compositions et procédés pour la modulation de récepteurs au lpa
CN104066729A (zh) * 2011-08-15 2014-09-24 英特穆恩公司 溶血磷脂酸受体拮抗剂
EA201492285A1 (ru) * 2012-06-20 2015-04-30 Ф. Хоффманн-Ля Рош Аг Соединения n-алкилтриазола в качестве антагонистов лизофосфатидной кислоты (lpar)

Also Published As

Publication number Publication date
CA2869564A1 (fr) 2013-12-27
CL2014003241A1 (es) 2015-03-20
KR20150011389A (ko) 2015-01-30
EA201492281A1 (ru) 2015-04-30
UA110310C2 (uk) 2015-12-10
JP2015520203A (ja) 2015-07-16
PE20142305A1 (es) 2015-01-16
EP2864301A1 (fr) 2015-04-29
MA37762B1 (fr) 2018-04-30
MX2014014711A (es) 2015-03-04
SG11201407228PA (en) 2014-12-30
IL236087A0 (en) 2015-02-01
HK1206339A1 (en) 2016-01-08
BR112014030674A2 (pt) 2017-06-27
WO2013189865A1 (fr) 2013-12-27
AU2013279513A1 (en) 2014-10-16
CN104395299A (zh) 2015-03-04
US20150133512A1 (en) 2015-05-14
CO7131357A2 (es) 2014-12-01
PH12014502363A1 (en) 2015-01-12
ZA201408167B (en) 2015-12-23
IN2014DN09352A (fr) 2015-07-17

Similar Documents

Publication Publication Date Title
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MA38398B1 (fr) Composés biaryle amides en tant qu'inhibiteurs de kinase
MA35285B1 (fr) Indazoles
MA40955A (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MA35576B1 (fr) Nouveaux composés
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA37886A1 (fr) Nouvelles pyridinones bicycliques
MA35271B1 (fr) Antagonistes de trpm8 et leur utilisation dans des traitements
MA54386B1 (fr) Modulateurs de trex1
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA38810A1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA39750B1 (fr) Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2
MA37879B1 (fr) Forme amorphe stabilisée d'agomélatine, procédé pour sa préparation et compositions pharmaceutiques la contenant
EA201490618A1 (ru) Замещенные 2-(хроман-6-илокси)тиазолы и их пременение в качестве фармацевтических средств
MA38206A1 (fr) Pyridyl-hydrazones pour le traitement de la tuberculose et de maladies associées